The effect of SGLT2 inhibitors on reducing blood glucose levels, even in non-diabetic HF patients, may contribute to lower the risks and complications of frailty, as it has been shown that hyperglycaemia is associated with cognitive impairment [55] and with low physical function [56] in frail hypertensive older adults. This evidence concerns the gene SLC5A2 and Hyperglycemia.